Shandong Xinhua Pharmaceutical Co Ltd (000756) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.11 Million ≈ $8.21 Million USD) by net assets (CN¥4.70 Billion ≈ $687.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Xinhua Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shandong Xinhua Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Shandong Xinhua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vitec Software Group AB (publ)
ST:VIT-B
|
0.023x |
|
Foshan Electrical and Lighting Co Ltd
SHE:000541
|
0.003x |
|
Jiangyin Electrical Alloy Co Ltd
SHE:300697
|
0.019x |
|
Sabine Royalty Trust
NYSE:SBR
|
8.048x |
|
MAP Aktif Adiperkasa Tbk PT
JK:MAPA
|
0.093x |
|
Pantoro Limited
F:RKN
|
-0.013x |
|
Sopharma AD
WAR:SPH
|
-0.018x |
|
Lily Group Co Ltd
SHG:603823
|
0.021x |
Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Shandong Xinhua Pharmaceutical Co Ltd (000756) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.22 Billion ≈ $763.48 Million |
CN¥367.61 Million ≈ $53.79 Million |
0.070x | +26.84% |
| 2023-12-31 | CN¥4.78 Billion ≈ $698.84 Million |
CN¥265.28 Million ≈ $38.82 Million |
0.056x | -68.13% |
| 2022-12-31 | CN¥4.35 Billion ≈ $636.53 Million |
CN¥758.24 Million ≈ $110.95 Million |
0.174x | +145.62% |
| 2021-12-31 | CN¥3.65 Billion ≈ $534.28 Million |
CN¥259.12 Million ≈ $37.92 Million |
0.071x | -42.72% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.25 Million |
CN¥420.19 Million ≈ $61.49 Million |
0.124x | +10.66% |
| 2019-12-31 | CN¥3.11 Billion ≈ $455.17 Million |
CN¥348.27 Million ≈ $50.96 Million |
0.112x | -3.33% |
| 2018-12-31 | CN¥2.80 Billion ≈ $409.22 Million |
CN¥323.91 Million ≈ $47.40 Million |
0.116x | -23.39% |
| 2017-12-31 | CN¥2.58 Billion ≈ $377.46 Million |
CN¥389.97 Million ≈ $57.07 Million |
0.151x | -28.45% |
| 2016-12-31 | CN¥2.08 Billion ≈ $304.27 Million |
CN¥439.35 Million ≈ $64.29 Million |
0.211x | +20.25% |
| 2015-12-31 | CN¥1.98 Billion ≈ $290.33 Million |
CN¥348.64 Million ≈ $51.02 Million |
0.176x | -- |
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more